EXPLORE THE SCIENCE
TL;DR: A 2026 pooled analysis in CNS Drugs combined two six-week trials of adults whose depression hadn’t responded well enough to an antidepressant. Adding the antipsychotic lumateperone instead of a placebo raised the share of people with side effects from 4…
Read article
TL;DR: A 2026 Phase I study in CNS Drugs found that a 400 mg powdered cannabidiol (CBD) formulation reached peak blood levels faster than oil-based Epidyolex, especially after a high-fat meal, while both products were generally well tolerated in healthy adults…
Read article
Repurposing antipsychotics and antidepressants with favorable safety profiles and blood-brain barrier permeability shows promise for glioblastoma (GBM) treatment, primarily through disrupting lysosomal function and inducing cell death. Highlights: Mechanism of…
Read article